Investor Presentation
Released
Released
Announcement PDF
Fast-acting nasal
spray treatment for
erectile dysfunction
Investor Overview | March 2024
Important notice
& Disclaimer
‣
Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd (Company) to provide general information about the Company. The information in this document is
in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has
taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.
‣
Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be
unlawful under the securities or other laws of that or any other jurisdiction.
‣
Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or
other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to
invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular
investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.
‣
Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified
by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on
information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to
risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable
but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in
such statements. There can be no assurance that actual outcomes will not differ materially from these statements.
‣
Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for
statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of
the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of
any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any
inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice.
‣
LTR Pharma Limited ACN 644 924 569
Investor Presentation
2
Introduction
Executive
Summary
Bringing to
market the first
nasal spray for ED
LTR Pharma is commercialising SPONTAN®
A ‘First in Class’ rapid, on demand nasal spray treatment
for Erectile Dysfunction (ED)
Successful Phase I Human Proof of Concept
Indicating 6x faster than oral administration of PDE5
inhibitors (i.e. Viagra)
Funded to progress the business
Raised $7 million as part of its ASX IPO December 2023
Disrupting the blockbuster PDE5 inhibitor market
Targeting to be the first PDE5 inhibitor nasal spray registered in
market estimated to reach US$6.0B in 2028
Clear commercial pathway
Commenced SPONTAN's bioequivalence clinical study to
expedite US and Australian regulatory filings within 1-2 years,
enable early Australian market access, and clinical package
preparation for licencing and regulatory discussions.
Investor Presentation
4
Investment Highlights
LTR Pharma positioned in a clear gap in the market
Expedited
path to market
Promising
proof of concept
Blockbuster
market with issues
Blue chip
partners
Multiple upcoming
value inflection
points
Repurposed drugs with
novel delivery methods
can reach the market in
the US and Australia
quickly
Demonstrated 6x faster
than oral administration
of competitor PDE5
inhibitors
Existing PDE5
inhibitors have a high
discontinuation rate due
poor efficacy and side
effects
Commercial
manufacturing
partnership with ASX
listed Mayne Pharma
Key pivotal clinical trial in
progress now;
Preparations for early
access in Australia
Potential
partnerships/licensing
Investor Presentation
5
Industry
overview
ED and its Causes
A major factor in
relationship breakdown
Psychological
causes
Physical
causes
Cardiovascular issues
Relationship problems
Stress / anxiety
Depression
Hormonal issues
Injury
Erectile disfunction (ED) is a medical
condition wherein an individual is
unable to get or keep an erection
for satisfactory sexual intercourse
Prevalence of ED with individuals with cardiovascular risk factors,
hypertension and diabetes, is reported as high as 50%
Investor Presentation
7
Prevalence in key markets
As risk factors become more prevalent, so does ED
USA
China
Aus
EU
~30m
~33m
Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
~150m
60.7%
of males 45y/o+
Investor Presentation
8
Current treatments
Gold standard are PDE5 inhibitors which have several drawbacks
Phosphodiesterase-5 (PDE5)
inhibitors are first-line treatments
Issues with
PDE5 inhibitors
Product
Main
Brand(s)
Time before sexual
activity for dose
Approval
Date (US)
Generic
availability
Does not work
for 30-35% of patients
Sildenafil
Viagra
1 hour+
1998
Yes
Long response time of
1 hour + affects spontaneity
Tadalafil
Cialis
1 hour+
2003
Yes
Adverse reactions
in 35% of patients
Vardenafil
Levitra,
Staxyn
1 hour+
2003
Yes
Avanafil
Stendra
30 minutes+
2012
No
= High discontinuation rate
Investor Presentation
9
Estimated Market size
Forecast to be US$6.0B market by 2028
US$6.0B
$5.94B
7.0% CAGR
US$5.0B
US$ billions
US$4.0B
$3.68B
US$3.0B
$2.58B
$2.76B
$2.95B
$3.38B
$3.16B
$3.61B
$3.87B
$4.15B
US$2.0B
US$1.0B
$1.11B
$1.18B
$1.27B
$1.36B
$1.45B
$1.56B
$1.67B
$1.79B
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
US$0.0B
US
ROW
Investor Presentation
10
The search for a new branded option
Significant opportunity for branded assets
Opportunity to capture
market share at higher margins
Generics have grown to 700M* units annually
‣ ‘Rapid erosion of branded volume following patent expiries
‣ No product differentiation in a fragmented market
‣ Low margins for currently marketed generics
Branded drugs
‣ Commands significantly higher price points / margins
‣ Demonstrates pricing power and demand for premium brands
SPONTAN as branded asset
‣ Market participants seeking new branded options to
differentiate in the marketplace
‣ Opportunity to capture market share through improved
therapy profile with higher margins than generics
Note: * 700M units claimed and does not include self-funded purchases
Investor Presentation
11
Nasal Administration
Delivery mechanism can solve many
of issues facing PDE5 inhibitors
Advantages vs oral administration
More rapid
onset of action
Higher rate
of absorption
Lower adverse
reactions
Less active
pharmaceutical
ingredients required
Less drug degradation
due to bypassing the
digestive system
Investor Presentation
12
Company
Overview
Company History
Progressed company substantially derisking the proposition
2020 - 2021
Acquired exclusive worldwide rights to
develop, manufacture and market SPONTAN®
through a licence agreement with SDS
Establishment of the
Scientific Advisory Board
in the field of Men’s Health
Validated the US FDA’s 505(b)(2)
regulatory pathway through an
expert regulatory review
2023
2022
Initial Public Offer (IPO)
Successfully completed an
oversubscribed IPO. The Company
listed on the ASX on 11 December
2023 and raised AU $7M.
Received early acceptance
from IP Australia for our
product trademark name
“SPONTAN”
Adopted Mayne Health
as a high-quality commercial
manufacturing partner to product
SPONTAN to GMP standards
Optimised delivery and commercial
development of its nasal formulation
with drug stability data from nasal
spray device developer
2024
Developed the
protocol for its
bioequivalence
study, and gained
ethics approval
2020 Proof of
Concept trial
results published in
2023 in The Journal
of Sexual Medicine
Completed
packaging studies
for final commercial
product ahead of
bioequivalence study
and commercial sales
Conducted crucial
derisking activities
before moving into
clinical development
Pivotal Trial Commences
Commenced SPONTAN's bioequivalence
clinical study to expedite regulatory
filings, enable early Australian market
access and preparation for licensing and
partnering discussions
Investor Presentation
14
SPONTAN® Overview
A novel delivery of a proven ED drug
Drug repurposing
Focused on changing the method of administration
of Vardenafil, an existing and approved drug
already in global markets since 2003
Intra-nasal delivery
Intra-nasal Vardenafil formulation, SPONTAN®,
is fast acting and low dose compared with the
incumbent oral ED treatment products on market
Expedited path to market
Builds on Vardenafil’s safety and efficacy data
package with upcoming bioequivalence study
in advance of FDA and TGA meetings
Investor Presentation
15
Competitive
Advantages
Mode of delivery
A faster acting
lower dose drug
formulation
with a better
safety profile
Nasal
Sildenafil
Tadalafil
Avanafil
Vardenafil
Oral
Oral
Oral
Oral
Low dosage
Rapid absorption
Quick onset of action
Higher bioavailability
Fewer side effects
Investor Presentation
16
Proof of concept Trial data
Confirmation of rapid onset effect
12 patients in a randomised, single dose
cross-over study of males aged between 24-45
The delivery of the SPONTAN nasal spray solution used a 100 ul
per dose nasal spray device manufactured by Aptar Pharma
The trial compared Vardenafil HC1 as SPONTAN®
nasal spray (4 mg) and as an oral tablet (10 mg)
Confirmation rapid onset of effect for SPONTAN of
~10 mins compared to 60 mins of existing oral ED drugs
The trial was published
in May 2023 with
The Journal of Sexual
Medicine confirmed
Peak concentration of drug in patient
within 10 mins suggesting patient will
respond shortly after administration
No severe adverse events
An acceptable safety profile
Investor Presentation
17
Pivotal Bioequivalence clinical study
Results expedite NDA filing
& ARTG registration in the US & Australia
Trial objective – study has commenced
To assess the relative bioavailability of Vardenafil following administration of SPONTAN ®
as a nasal spray compared to Vardenafil tablets
Subjects
Recruitment commenced in February of 18 healthy adult male subjects
Trial design
A single-dose, randomised, open-label, 2-treatment, 2-period crossover study of SPONTAN®
nasal spray (5 mg Vardenafil: a single 2.5 mg spray in each nostril) compared to Vardenafil
tablets (10 mg Vardenafil)
Outcome
Successful completion of the bioequivalence trial provides data for early access scheme
in Australia and potential partnering and licensing deals
Investor Presentation
18
Expedited path to market
LTR requires FDA and TGA approval to operate in the US & Australia
FDA
(US)
TGA
(AUS)
Targeting a 505 (b)(2) approval
pathway regulatory strategy, on
basis it is “repurposing” of an
existing approved drug
Previous approval of oral tablet
Vardenafil by the FDA would allow
inclusion of existing safety and
efficacy clinical and nonclinical data
Targeting NDA
filing at beginning
of CY 2025
Targeting Category 1 - Type F
Application process is expected
to be available to the Company
Given the existing safety profile of
Vardenafil, the regulatory pathways
for repurposed drugs allows for
expedited application
Targeting filing at
middle of CY 2025
SPONTAN® may be made available to patients via the TGA's SAS or APS
on an as needs basis and subject to the relevant regulatory framework
Investor Presentation
19
Upcoming Key Milestones
Multiple value inflection points in Calendar Year 2024
Pivotal
clinical trial
‣ Recruitment
Early access
use Australia
Pre submission
meetings with
FDA & TGA
2nd Nasal Spray
product
Licensing /
Partnering
discussions
‣ Dosing
‣ Results
Investor Presentation
20
Financial Summary
Strong Funding to Commercial Outcomes
(ASX:LTP) Public Market Overview (15 March 2024)
Share Price
A$0.32
52-week range
A$0.25 – A$0.41
Market Cap
A$46.00M
Cash equivalents (31 December 2023)
A$6.01M
Top 20 shareholder percentage
57.94%
Investor Presentation
21
Contact
investors@ltrpharma.com
www.ltrpharma.com
Share your feedback
Discover